Lung Cancer

Oncology
92
Pipeline Programs
30
Companies
50
Clinical Trials
4 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
13
8
52
2
14
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1354%
Small Molecule
1042%
Cell Therapy
14%
+ 109 programs with unclassified modality

On Market (3)

Approved therapies currently available

Eli Lilly and Company
ALIMTAApproved
pemetrexed
Eli Lilly and Company
injection2004
U
CARBOPLATINApproved
carboplatin
Unknown Company
intravenous2009
Amgen
NPLATEApproved
romiplostim
Amgen
Thrombopoietin Receptor Agonist [EPC]subcutaneous2008

Competitive Landscape

46 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
7 programs
1
1
4
1
AMG 510Phase 21 trial
NPLATE(Romiplostim)Phase 25 trials
filgrastimPhase 21 trial
sorafenibPhase 2Small Molecule1 trial
PanitumumabPhase 1/2Monoclonal Antibody1 trial
+2 more programs
Active Trials
NCT00101907Terminated41Est. Apr 2008
NCT00094835Completed51Est. Mar 2007
NCT05118854Recruiting27Est. Oct 2027
+7 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
2
1
ALIMTA(Alimta)Phase 21 trial
DocetaxelPhase 21 trial
Active Trials
NCT00508144Completed64Est. Dec 2015
NCT00193427Completed75Est. Dec 2008
Alliance Pharmaceuticals
2
12
3
carboplatinPhase 31 trial
carboplatinPhase 35 trials
carboplatinPhase 31 trial
Seneca Valley virus-001Phase 21 trial
carboplatinPhase 21 trial
+21 more programs
Active Trials
NCT04957433Unknown1,000Est. Dec 2023
NCT00899535Completed70Est. Feb 2013
NCT02989974Completed214Est. Apr 2019
+29 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
13 programs
1
7
2
T790M+ TestingPhase 31 trial
T790M+ TestingPhase 31 trial
AZD9291Phase 21 trial
OsimertinibPhase 2Small Molecule1 trial
PembrolizumabPhase 2Monoclonal Antibody
+8 more programs
Active Trials
NCT05557487Recruiting6,618Est. Dec 2028
NCT05832008Active Not Recruiting825Est. Jun 2026
NCT00621361Completed62Est. Feb 2012
+12 more trials
M&
7 programs
2
2
Bintrafusp alfaPhase 31 trial
Uridine 5'-TriphosphatePhase 31 trial
EMD 521873Phase 11 trial
TILT-123Phase 11 trial
Care coordination toolN/A1 trial
+2 more programs
Active Trials
NCT03694054Completed57Est. Mar 2019
NCT02020252Completed120Est. Dec 2018
NCT00879866CompletedEst. Sep 2012
+3 more trials
Pfizer
PfizerNEW YORK, NY
5 programs
1
2
cisplatinPhase 31 trial
gemcitabine hydrochloridePhase 31 trial
carboplatinPhase 22 trials
Conversational Agent/ChatbotN/A1 trial
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)N/A
Active Trials
NCT04347161Active Not Recruiting75Est. Oct 2026
NCT02592876Terminated81Est. Apr 2018
NCT00387660Completed80Est. Jan 2009
+2 more trials
DS
Daiichi SankyoChina - Shanghai
3 programs
1
1
PatritumabPhase 3Monoclonal Antibody1 trial
soblidotinPhase 22 trials
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)N/A
Active Trials
NCT00064220CompletedEst. Dec 2005
NCT00061854CompletedEst. May 2005
NCT02134015Terminated145Est. Nov 2016
Sanofi
SanofiPARIS, France
2 programs
1
cisplatinPhase 35 trials
BevacizumabN/AMonoclonal Antibody5 trials
Active Trials
NCT05584670Recruiting542Est. Jun 2028
NCT01339039Terminated26Est. Apr 2017
NCT00881504Terminated9Est. Dec 2011
+7 more trials
Qilu Pharmaceutical
1
QL1706Phase 31 trial
GefitinibN/ASmall Molecule1 trial
Active Trials
NCT03381430UnknownEst. Dec 2025
NCT05690945Active Not RecruitingEst. Dec 2029
Genesis Therapeutics
1
99mTc-3PRGD2 injectionPhase 31 trial
Active Trials
NCT04233476CompletedEst. May 2021
Ionis Pharmaceuticals
1 program
1
ISIS 3521Phase 31 trial
Active Trials
NCT00017407CompletedEst. Sep 2002
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
IRSW-MIMPhase 2/31 trial
Active Trials
NCT06478108RecruitingEst. Dec 2033
Abbott
AbbottABBOTT PARK, IL
1 program
1
Nutritional AssessmentPhase 2/31 trial
Active Trials
NCT01048970Unknown120Est. Dec 2010
Bristol Myers Squibb
1
1
KOS-862Phase 23 trials
DasatinibPhase 1/2Small Molecule1 trial
Engaged Approach to Lung Cancer ScreeningN/A1 trial
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)N/A
KY LEADS Survivorship CareN/A
+3 more programs
Active Trials
NCT06327074Active Not Recruiting40Est. Dec 2026
NCT03276429Completed650Est. Dec 2018
NCT03382496Completed1,462Est. Dec 2020
+5 more trials
Genentech
7 programs
2
2
3
CarboplatinPhase 2
IrinotecanPhase 21 trial
MPDL3280APhase 21 trial
BevacizumabPhase 1/2Monoclonal Antibody1 trial
docetaxelPhase 1/21 trial
+2 more programs
Active Trials
NCT00424840Terminated12Est. Mar 2014
NCT01302808Completed17Est. Dec 2014
NCT00411593Withdrawn0Est. May 2007
+3 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
6 programs
1
1
3
BIBW 2992Phase 21 trial
BIBW 2992Phase 21 trial
NintedanibPhase 2Small Molecule1 trial
AfatinibPhase 1/2Small Molecule1 trial
Dasatinib - 1APhase 11 trial
+1 more programs
Active Trials
NCT02445183Completed250Est. Sep 2020
NCT01999985Completed25Est. May 2019
NCT02768337Terminated26Est. Aug 2021
+3 more trials
Varian Medical Systems
4 programs
1
One fraction stereotactic body radiotherapyPhase 21 trial
Continuous Positive Airway PressureN/A1 trial
Stereotactic Body RadiotherapyN/A1 trial
Thoracic radiotherapyN/A1 trial
Active Trials
NCT05142358CompletedEst. Jan 2026
NCT02357992CompletedEst. Sep 2021
NCT04863027CompletedEst. Nov 2022
+1 more trials
Novartis
NovartisBASEL, Switzerland
3 programs
3
EGF816Phase 21 trial
ErlotinibPhase 2Small Molecule
Gleevec and TaxoterePhase 21 trial
Active Trials
NCT03292133Terminated11Est. Mar 2025
NCT00222144Completed23Est. Nov 2010
Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
1
Vinorelbine cisplatin radiotherapyPhase 21 trial
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)N/A
Active Trials
NCT01839032Completed70Est. Oct 2008
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
2 programs
1
1
rubitecanPhase 21 trial
PembrolizumabPhase 1Monoclonal Antibody
Active Trials
NCT00005872CompletedEst. Apr 2004
CT
1
1
Anlotinib HydrochloridePhase 21 trial
TQB2450Phase 1/21 trial
Active Trials
NCT03983928UnknownEst. Dec 2020
NCT03703596UnknownEst. Nov 2020
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
ZimberelimabPhase 2Monoclonal Antibody1 trial
ZimberelimabPhase 2Monoclonal Antibody
Active Trials
NCT05633667Recruiting270Est. Sep 2029
Teva
TevaIsrael - Petach Tikva
1 program
1
Arsenic TrioxidePhase 21 trial
Active Trials
NCT01470248Completed20Est. Jan 2016
Heidelberg Pharma
1
EBUS TBNFPhase 21 trial
Active Trials
NCT01145924Unknown50Est. Aug 2010
Roche
1 program
1
ErlotinibPhase 2Small Molecule
H
1 program
1
FruquintinibPhase 2Small Molecule1 trial
Active Trials
NCT03684967Withdrawn0Est. Sep 2019
Providence Therapeutics
1
Induction DurvalumabPhase 2Monoclonal Antibody
Sutro Biopharma
Sutro BiopharmaSOUTH SAN FRANCISCO, CA
1 program
1
Luveltamab tazevibulinPhase 21 trial
Active Trials
NCT06555263Withdrawn0Est. May 2025
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
NKTR-255Phase 21 trial
Active Trials
NCT05632809RecruitingEst. Dec 2027
Arcus Biosciences
1 program
1
ZimberelimabPhase 2Monoclonal Antibody

+16 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Sanoficisplatin
Qilu PharmaceuticalQL1706
Merck & Co.Bintrafusp alfa
AmgenRomiplostim
Genesis Therapeutics99mTc-3PRGD2 injection
AmgenRomiplostim
AstraZenecaT790M+ Testing
AstraZenecaT790M+ Testing
Alliance Pharmaceuticalscarboplatin
Daiichi SankyoPatritumab
AmgenRomiplostim
Alliance Pharmaceuticalscarboplatin
AmgenRomiplostim
Alliance Pharmaceuticalscarboplatin
Sanoficisplatin

Showing 15 of 48 trials with date data

Clinical Trials (50)

Total enrollment: 13,255 patients across 50 trials

Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma

Start: Oct 2004Est. completion: Mar 200857 patients
Phase 4Completed

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Start: Feb 2023Est. completion: Dec 2029
Phase 3Active Not Recruiting
NCT05061823Merck & Co.Bintrafusp alfa

Bintrafusp Alfa Program Rollover Study

Start: Dec 2021Est. completion: Mar 2025
Phase 3Completed
NCT03937154AmgenRomiplostim

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Start: Feb 2020Est. completion: May 2027145 patients
Phase 3Active Not Recruiting
NCT04233476Genesis Therapeutics99mTc-3PRGD2 injection

99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer

Start: Oct 2019Est. completion: May 2021
Phase 3Completed
NCT03343847AmgenRomiplostim

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.

Start: Jan 2018Est. completion: Jul 20210
Phase 3Withdrawn

T790M Plasma Testing Methodology Comparison and Clinical Validation

Start: Dec 2016Est. completion: Oct 2018256 patients
Phase 3Completed

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Start: Sep 2015Est. completion: Apr 20193,017 patients
Phase 3Completed

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Start: Aug 2015Est. completion: Jun 2031420 patients
Phase 3Active Not Recruiting

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Start: Mar 2014Est. completion: Nov 2016145 patients
Phase 3Terminated
NCT01444417AmgenRomiplostim

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Start: Jan 2012Est. completion: Feb 201562 patients
Phase 3Completed

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Start: Feb 2010Est. completion: Mar 2018313 patients
Phase 3Terminated
NCT01071954AmgenRomiplostim

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

Start: Dec 2009Est. completion: Jan 201766 patients
Phase 3Completed

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Start: Dec 2009Est. completion: Aug 2012195 patients
Phase 3Completed

Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy

Start: Nov 2009Est. completion: Aug 2012375 patients
Phase 3Completed

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

Start: Aug 2009Est. completion: Jan 2018240 patients
Phase 3Completed

Taxotere New Indication - Gastric Cancer Treatment Registration Trial

Start: Nov 2008Est. completion: Jun 2012243 patients
Phase 3Completed

A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Start: Jun 2008Est. completion: May 2017390 patients
Phase 3Completed

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Start: Mar 2008731 patients
Phase 3Unknown
NCT00415532AmgenRomiplostim

Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

Start: Dec 2006Est. completion: May 2009234 patients
Phase 3Completed

Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer

Start: Oct 2005Est. completion: May 2015434 patients
Phase 3Completed

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation

Start: Apr 2005Est. completion: Jan 2008317 patients
Phase 3Completed

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

Start: Nov 200286 patients
Phase 3Completed

Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer

Start: Oct 2002Est. completion: Sep 2006861 patients
Phase 3Completed

Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

Start: Feb 2002Est. completion: Mar 2008243 patients
Phase 3Completed

Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma

Start: Dec 2001Est. completion: May 2009220 patients
Phase 3Completed
NCT00210080Merck & Co.Uridine 5'-Triphosphate

A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

Start: Apr 2001Est. completion: Dec 2003700 patients
Phase 3Completed

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

Start: Oct 2000Est. completion: Sep 2002
Phase 3Completed

Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Start: Jul 2000Est. completion: Feb 2004
Phase 3Completed
NCT00005093Pfizergemcitabine hydrochloride

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

Start: Dec 1999Est. completion: May 2001
Phase 3Completed

Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer

Start: Mar 1999
Phase 3Completed

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

Start: Jul 1998Est. completion: Apr 2009366 patients
Phase 3Completed

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Start: May 1998Est. completion: Aug 2005480 patients
Phase 3Completed

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer

Start: Oct 1997Est. completion: Jan 2006584 patients
Phase 3Completed

Interventional Software for Multi-immunotherapy of Solid Tumors

Start: Apr 2024Est. completion: Dec 2033
Phase 2/3Recruiting
NCT01048970AbbottNutritional Assessment

Effect on the Nutritional and Inflammatory Status of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement in Patients With Advanced Lung Cancer

Start: Oct 2009Est. completion: Dec 2010120 patients
Phase 2/3Unknown

Docetaxel in Head and Neck Cancer

Start: Dec 2002Est. completion: Jul 2010439 patients
Phase 2/3Completed

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Start: Oct 2002Est. completion: Mar 2006432 patients
Phase 2/3Completed

Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer

Start: Oct 1998Est. completion: May 2003610 patients
Phase 2/3Completed

Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer

0
Phase 2Withdrawn

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

0
Phase 2Withdrawn
NCT06555263Sutro BiopharmaLuveltamab tazevibulin

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Start: Aug 2024Est. completion: May 20250
Phase 2Withdrawn

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Start: Apr 2024Est. completion: Jul 202776 patients
Phase 2Active Not Recruiting
NCT06236516Varian Medical SystemsOne fraction stereotactic body radiotherapy

One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

Start: Feb 2024Est. completion: Aug 2025
Phase 2Completed
NCT05323617AmgenRomiplostim

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

Start: Aug 2023Est. completion: Feb 20250
Phase 2Withdrawn

Study of Novel Treatment Combinations in Patients With Lung Cancer

Start: Mar 2023Est. completion: Sep 2029270 patients
Phase 2Recruiting

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Start: Jan 2023Est. completion: Dec 2027
Phase 2Recruiting
NCT04933942AmgenRomiplostim

Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma

Start: Sep 2022Est. completion: Dec 20220
Phase 2Withdrawn

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Start: Mar 2022Est. completion: Oct 202727 patients
Phase 2Recruiting

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Start: Nov 2020Est. completion: May 2027101 patients
Phase 2Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

14 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 13,255 patients
30 companies competing in this space